Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (abstract)

Update Item Information
Identifier 20170403_nanos_sciplatform1_01-abstract
Title Tocilizumab in Patients With Giant Cell Arteritis: Results From a Phase 3 Randomized Controlled Trial (abstract)
Creator Susan Mollan; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Neil Collinson; John Stone
Affiliation (SM) University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham B15 2GW, United Kingdom; (KT) (SD) (NC) Roche Products Ltd., Welwyn Garden City, United Kingdom; (MK) Genentech, South San Francisco, California; (JS) Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts
Subject Vascular Disorders; Neuro-ophth & Systyemic Disease (eg. MS, MG, Thyroid); Optic neuropathy
Description The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized, double-blind, placebo-controlled trial.1 Data for week 52 outcome measures are presented.
Date 2017
Language eng
Format application/pdf
Type Text
Source 2017 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2017: Scientific Platform I
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2013. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s67x067m
Setname ehsl_novel_nam
ID 1273002
Reference URL https://collections.lib.utah.edu/ark:/87278/s67x067m
Back to Search Results